

Certificate of Analysis

EGFR (L861Q), active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-627, 14-627-K, 14-627M

Parent Lot # 31355U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal GST-tagged, recombinant human EGFR, amino acids 696–end containing the mutation L861Q. This mutation has been associated with non-small cell lung cancer patients who demonstrate clinical responsiveness to the tyrosine kinase inhibitor gefitinib (Iressa, ZD1839).

Expressed by baculovirus in Sf21 insect cells. Purified using glutathione-agarose. Purity 79.5% by SDS-PAGE and Coomassie blue staining. MW = 85.8kDa.

Formulation: 2.252mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.

Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.


Specific Activity (Parent lot# 31355U): 44U/mg, where one unit of EGFR, active activity is defined as 1nmol phosphate incorporated into 0.1mg/ml poly(Glu, Tyr) (4:1) per minute at 30°C with a final ATP concentration of 100µM.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 17.9–225ng of this lot of enzyme phosphorylated 0.1mg/ml poly(Glu,Tyr) (4:1) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as EGFR with the translated native sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **Poly(Glu, Tyr) (4:1):** Use at a final assay concentration of 0.1mg/ml. Prepare a 1mg/ml stock. Add 2.5µl of stock per assay point.
3. **EGFR, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 17.9–225ng per assay point.
4. **[γ -³³P]ATP:** 2.5 x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5µl of 10 x reaction buffer per assay to wells
2. Add 2.5µl of **poly(Glu, Tyr) (4:1)**.
3. Add **2.5µl (17.9–225ng) EGFR, active**.
4. Add 5µl of dH₂O.
5. Add 10µl of diluted [γ -³³P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5µl of 3% phosphoric acid.
8. Transfer a 10µl aliquot onto the appropriate area of a **Filtermat A**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

EGFR (L861Q) Sequence Information

<u>Protein</u>	Human EGFR (L861Q)
<u>Tags</u>	N-Terminal GST
<u>Native sequence</u>	G241 of recombinant sequence is equivalent to G696 of native human EGFR
<u>Accession number</u>	GenBank X00588

Recombinant EGF Receptor amino acid sequence:

```

1  MSPILGYWKI  KGLVQPTRLL  LEYLEEKYEE  HLYERDEGDK  WRNKKFELGL  EFPNLPYYID
61  GDVKLTQSMa  IIRYIADKHN  MLGGCPKERA  EISMLEGAVL  DIRYGVSRIA  YSKDFETLKV
121 DFLSKLPEML  KMFEDRLCHK  TYLNGDHVTH  PDFMLYDALD  VVLYMDPMCL  DAFPKLVCFK
181 KRIEAIQID  KYLKSSKYIA  WPLQGQWATF  GGGDHPPKSD  LEVLFQGPEF  KGMGIRNSKG
241 GEAPNQALLR  ILKETEFKKI  KVLGSGAFGT  VYKGLWIPEG  EKVKIPVAIK  ELREATSPKA
301 NKEILDEAYV  MASVDNPHVC  RLLGICLTST  VQLITQLMPF  GCLLDYVREH  KDNIGSQYLL
361 NWCVQIAKGM  NYLEDRLVH  RDLAARNVLV  KTPQHVKITD  FGLAKQLGAE  EKEYHAEGGK
421 VPIKWMALES  ILHRIYTHQS  DVWSYGVTVW  ELMTFGSKPY  DGIPASEISS  ILEKGERLPQ
481 PPICTIDVYM  IMVKCWMIDA  DSRPKFRELI  IEFKSMARDP  QRYLVIQGDE  RMHLPSPDTS
541 NFYRALMDEE  DMDDVDDADE  YLIPQQGFFS  SPSTSRTPLL  SLSATSNNNS  TVACIDRNL
601 QSCPIKEDSF  LQRYSSDPTG  ALTEDSIDDT  FLPVPEYINQ  SVPKRPAGSV  QNPVYHNQPL
661 NPAPSRDPHY  QDPHSTAVGN  PEYLNTVQPT  CVNSTFDSPA  HWAQKGSQHI  SLDNPDYQQD
721 FFPKEAKPNG  IFKGSTAENA  EYLRVAPQSS  EFIGA
  
```

Recombinant EGF Receptor nucleotide sequence:

```

1  atgtccccta  tactaggtta  ttggaataat  aagggccttg  tgcaaccac  tcgacttctt
61  ttggaatatc  ttgaagaaaa  atatgaagag  catttgatat  agcgcgatga  aggtgataaa
121 tggcgaaaca  aaaagtttga  attgggtttg  gagtttccca  atcttcctta  ttatatgat
181 ggtgatgtta  aattaacaca  gtctatggcc  atcatagctt  atatagctga  caagcacaac
241 atgttgggtg  gttgtccaaa  agagcgtgca  gagatttcaa  tgcttgaagg  agcggttttg
301 gatattagat  acggtgtttc  gagaattgca  tatagtaaag  actttgaaac  tctcaaagtt
361 gattttctta  gcaagctacc  tgaaatgctg  aaaatgttcg  aagatcgttt  atgtcataaa
421 acatatatta  atggtgatca  tgtaaccat  cctgacttca  tggttgatga  cgctcttgat
481 gttgttttat  acatggaccc  aatgtgcctg  gatgcgttcc  caaaattagt  ttgttttaaa
541 aaacgtattg  aagctatccc  acaaattgat  aagtacttga  aatccagcaa  gtatatagca
601 tggcctttgc  agggctggca  agccacgttt  ggtggtggcg  accatcctcc  aaaatcggat
661 ctggaagttc  tgttccaggg  gcccgatttc  aaaggcatgg  ggatccggaa  ttcaaagggt
721 ggagaagctc  ccaaccaagc  tctcttgagg  atcttgaagg  aaactgaatt  caaaaagatc
781 aaagtgtctg  gctccggtgc  gttcggcagc  gtgtataagg  gactctggat  cccagaaggt
841 gagaaagtta  aaattcccgt  cgctatcaag  gaattaagag  aagcaacatc  tccgaaagcc
901 aacaaggaaa  tcctcgatga  agcctacgtg  atggccagcg  tggacaaccc  ccacgtgtgc
961 cgctgtctgg  gcatctgcct  cacctccacc  gtgcaactca  tcacgcagct  catgcccttc
1021 ggctgcctcc  tggactatgt  ccgggaacac  aaagacaata  ttggctccca  gtacctgtct
1081 aactggtgtg  tgcagatcgc  aaagggcatg  aactacttgg  aggaccgtcg  cttggtgcac
1141 cgcgacctgg  cagccaggaa  cgtactgggt  aaaacaccgc  agcatgtcaa  gatcacagat
1201 tttgggctgg  ccaaacagct  ggggtcggaa  gagaaagaat  accatgcaga  aggaggcaaa
1261 gtgcctatca  agtggtatgg  attggaatca  attttacaca  gaatctatac  ccaccagagt
1321 gatgtctgga  gctacggggt  gaccgtttgg  gagttgatga  cctttggatc  caagccatat
1381 gacggaatcc  ctgccagcga  gatctcctcc  atcctggaga  aaggagaacg  cctccctcag
1441 ccacccatat  gtaccatcga  tgtctacatg  atcatggtca  agtgctggat  gatagacgca
1501 gatagtgcgc  caaagttccg  tgagttgatc  atcgaattct  ccaaaatggc  ccgagacccc
1561 cagcgtacc  ttgtcattca  gggggatgaa  agaatgcatt  tgccaagtcc  tacagactcc
1621 aacttctacc  gtgcctgat  ggatgaagaa  gacatggacg  acgtggtgga  tgccgacgag
1681 tacctcatcc  cacagcaggg  cttcttcagc  agcccctcca  cgtcacggac  tcccctcctg
  
```

Certificate of Analysis

```

1741 agctctctga gtgcaaccag caacaattcc accgtggctt gcattgatag aaatgggctg
1801 caaagctgtc ccatcaagga agacagcttc ttgcagcgat acagctcaga cccacaggc
1861 gccttgactg aggacagcat agacgacacc ttctctccag tgctgaata cataaaccag
1921 tccgttccca aaaggccgc tggctctgtg cagaatcctg tctatcaca tcagcctctg
1981 aaccccgcg cccagcagaga cccacactac caggaccccc acagcactgc agtgggcaac
2041 cccgagtatc tcaacactgt ccagcccacc tgtgtcaaca gcacattcga cagccctgcc
2101 cactggggcc agaaaggcag ccaccaaatt agcctggaca accctgacta ccagcaggac
2161 ttctttccca aggaagccaa gccaaatggc atctttaagg gctccacagc tgaaaatgca
2221 gaatacctaa gggtcgcgcc acaaagcagt gaatttattg gagcatga

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.